Founded out of Aarhus University in 2004, Mindway AI builds artificial intelligence-driven tools to prevent problem gambling.
Johns Hopkins University's oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Amgen and Pfizer-backed oncology therapy developer NexImmune has filed to raise up to $86.3m in an IPO on the Nasdaq Global Market.
Novo and Pfizer are among the investors set to exit the cancer therapy developer, which has set a $100m target for its initial public offering.
Bennett Coleman & Co, Globe Telecom and Tencent are set to exit the story sharing community operator in a cash-and-stock acquisition transaction by Naver.
Lilly Asia Ventures is the largest shareholder of liver disease therapy developer Terns, which closed a $97.7m round earlier this month.
Columbia University is in line for an exit as cancer drug developer Vor files for its initial public offering.
The immunotherapy developer plans to go public in the US having raised $565m since being formed to develop assets of a defunct Oxford spinout.
The telecoms group has bought a 51% stake in its portfolio company Invenium, a mobility data analytics company spun out of TU Graz.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
